Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

Affiliations

¹ Department of Hematology Oncology, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA. Snghafouri@mednet.ucla.edu.
² UCLA Lymphoma Program, Division of Hematology & Oncology, Department of Medicine, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
³ Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
⁴ Department of Hematology Oncology, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.

Sanaz Ghafouri et al. Bone Marrow Transplant. 2021 Apr.

. 2021 Apr;56(4):974-977.

doi: 10.1038/s41409-020-01099-4. Epub 2020 Nov 10.

¹ Department of Hematology Oncology, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA. Snghafouri@mednet.ucla.edu.
² UCLA Lymphoma Program, Division of Hematology & Oncology, Department of Medicine, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
³ Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.
⁴ Department of Hematology Oncology, UCLA Medical Center, 757 Westwood Plaza, Los Angeles, CA, 90095, USA.

No abstract available

Conflict of interest statement

SG and MM have no conflict of interest. JT received research funding form BMS, Kite, ImmunGene. SL is consultant for BMS.

1. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62. doi: 10.1038/nrclinonc.2017.148. - DOI - PMC - PubMed
1. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56. doi: 10.1056/NEJMoa1804980. - DOI - PubMed
1. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31–42. doi: 10.1016/S1470-2045(18)30864-7. - DOI - PMC - PubMed
1. Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134:860–6. doi: 10.1182/blood.2019001694. - DOI - PMC - PubMed
1. Bennani NN, Maurer MJ, Nastoupil LJ, Jain MD, Chavez JC, Cashen AF, et al. Experience with axicabtagene ciloleucel (Axi-cel) in patients with secondary cns involvement: results from the US lymphoma CAR T consortium. Blood. 2019;134:763. doi: 10.1182/blood-2019-129097. - DOI